Gevorg Tamamyan: We Can Do More…
Gevorg Tamamyan, Editor-in-Chief and Co-Founder of OncoDaily, shared on LinkedIn:
”Coming from the developing world, I know exactly what it means when something exists, when it could save a life, but it is simply not accessible to you. When you know there is a chance to save a patient, but that chance is blocked because of money, nothing feels more cruel.
Truly, injustice in health is the worst form of injustice.
For a person who knows that their child, a family member, or a loved one could be saved, but cannot be, simply because they have no money, this is the most devastating reality imaginable.
And today, this gap is not shrinking. It is growing.
We speak constantly about innovation, about new treatments, new diagnostics, but what do we actually see? These innovations are widening the gap, increasing suffering, instead of easing it.
Why is it that vincristine, MTX, or cytarabine, some of the most effective cancer drugs ever developed, can cost just a few dollars, while many of the new drugs, difficult even to pronounce, cost close to a million dollars for a single patient?
What are we doing wrong?
Why has the environment changed in a way that creates more disparity rather than less?
Over the years, we have built so many obstacles to innovation, to creativity, to those who want to create and improve medicine. How many years does it now take to develop a new drug? How much does it cost and why?
Some will say this “overprotection” exists for safety and quality. And I challenge that assumption.
Has anyone calculated how many lives we are losing because of this overprotection? Has anyone truly analyzed the balance between risk and benefit?
I am not saying we don’t need oversight. I am not saying we don’t need regulation. But regulation should enable progress, not block it.
Has anyone analyzed how many small and medium-sized biotech companies have gone bankrupt simply because they could not survive long enough, and, as a result, how many potentially life-saving drugs are still sitting on shelves, never approved, never reaching patients?
Some of them could have been the next imatinib or doxorubicin, but they never made it out of the lab.
So what should we do? What can we do as a society, as individuals, as organizations?
When we founded OncoDaily, we never imagined that, so soon, it would become what it is today. Our goal was simple: to democratize medical media. To give a voice to everyone. And that is exactly what we did, and that, I believe, was the key to our success. Our mission was to become the voice of oncology. And we are.
But raising problems is not enough.
OncoDaily will now go further, suggesting solutions and, most importantly, initiating and creating real actions to make modern cancer care accessible to everyone. From prevention to diagnosis, from treatment to follow-up.
Step by step, we can make it happen. We will start from oncology and will penetrate other fields of medicine.
We built OncoDaily from zero and in just 2 years it became a global leader. And we can do more. ”
Stay updated with Hemostasis Today.
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event